0.14
0.14 (0%)
As of Feb 14, 2025
Cns Pharmaceuticals, Inc. [CNSP]
Source:
Company Overview
Cns Pharmaceuticals, Inc is a clinical pharmaceutical company organizedas a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of brain and centralnervous system tumors, based on intellectual property that we license under license agreements with Cortice Biosciences, Inc. (“Cortice”)and own pursuant to a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. (“Reata”).
| Country | United States |
| Headquarters | houston, texas |
| Phone Number | 1-800-946-9185 |
| Industry | manufacturing |
| CEO | John Climaco |
| Website | www.cnspharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-14.9 |
| Net Income | $-14.9 |
| Net Cash | $5.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -285.7% |
| Profit as % of Stockholder Equity | -240.6% |
Management Effectiveness
| Return on Equity | -240.6% |
| Return on Assets | -170.8% |
| Turnover Ratio | |
| EBITA | $-14.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $8.7 |
| Total Liabilities | $2.5 |
| Operating Cash Flow | $-17.1 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $23 |
